The global cost of epilepsy: A systematic review and extrapolation.
cost
epilepsy
global
per person
prevalence
regional
total
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
29
12
2021
received:
22
10
2021
accepted:
29
12
2021
pubmed:
24
2
2022
medline:
14
4
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
Global action for epilepsy requires information on the cost of epilepsy, which is currently unknown for most countries and regions of the world. To address this knowledge gap, the International League Against Epilepsy Commission on Epidemiology formed the Global Cost of Epilepsy Task Force. We completed a systematic search of the epilepsy cost-of-illness literature and identified studies that provided a comprehensive set of direct health care and/or indirect costs, followed standard methods of case identification and cost estimation, and used data on a representative population or subpopulation of people with epilepsy. Country-specific costs per person with epilepsy were extracted and adjusted to generate an average cost per person in 2019 US dollars. For countries with no cost data, estimates were imputed based on average costs per person of similar income countries with data. Per person costs for each country were then applied to data on the prevalence of epilepsy from the Global Burden of Disease collaboration adjusted for the treatment gap. One hundred one cost-of-illness studies were included in the direct health care cost database, 74 from North America or Western Europe. Thirteen studies were used in the indirect cost database, eight from North America or Western Europe. The average annual cost per person with epilepsy in 2019 ranged from $204 in low-income countries to $11 432 in high-income countries based on this highly skewed database. The total cost of epilepsy, applying per person costs to the estimated 52.51 million people in the world with epilepsy and adjusting for the treatment gap, was $119.27 billion. Based on a summary and extrapolations of this limited database, the global cost of epilepsy is substantial and highly concentrated in countries with well-developed health care systems, higher wages and income, limited treatment gaps, and a relatively small percentage of the epilepsy population.
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
892-903Informations de copyright
© 2022 International League Against Epilepsy.
Références
Guekht A, Brodie M, Secco M, Li S, Volkers N, Wiebe S. The road to a World Health Organization global action plan on epilepsy and other neurological disorders. Epilepsia. 2021;62(5):1057-63.
Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015;15:245.
Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics. 2008;26(6):463-76.
Begley CE, Durgin TL. The direct healthcare cost of epilepsy in the United States: a systematic review of estimates. Epilepsia. 2015;56(9):1376-87.
Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Costs of disorders of the brain in Europe. Eur J Neurol. 2005;12:1-27.
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155-62.
Gao L, Hu H, Zhao FL, Li SC. Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples. PLoS One. 2016;11(1):1-17.
Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement. 2010;6(2):98-103.
Institute for Health Metrics and Evaluation. Global health data exchange download 2019. http://ghdx.healthdata.org/gbd-2019. Accessed October 31, 2019.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, et al. Research Electronic Data Capture (REDCap)-a metadata driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
Giussani G, Canelli V, Bianchi E, Franchi C, Nobili A, Erba G, et al. A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy Behav. 2016;55:30-7.
Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F, EPICOS Group. Direct healthcare cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia. 2004;45(2):171-8.
World Health Organization. Epilepsy: a public health imperative. 2019. https://apps.who.int/iris/handle/10665/325440?show=full. Accessed September 16, 2019.
Kwan P, Brodie MJ. Early identification of drug-resistant epilepsy. N Engl J Med. 2000;342(5):314-9.
Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019;22(9):1026-32.
World Bank. Inflation, GDP deflator (annual %). 2020. https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG. Accessed July 15, 2021.
World Bank 2019 PPP exchange rate. 2020. https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG. Accessed July 15, 2021.
Global health expenditure database. Geneva, Switzerland: World Health Organization; 2017.
World Bank. International Monetary Fund world economic outlook (October-2019). January 21, 2020. https://statisticstimes.com/economy/countries-by-gdp-capita.php#:~:text=World%20bank%20%20%20%20Rank%20%20,%20%202018%20%2071%20more%20rows%20. Accessed July 15, 2021.
World Bank. The world by income. https://datatopics.worldbank.org/world-development-indicators/images/figures-png/world-by-income-sdg-atlas-2018.pdf. Accessed July 15, 2021.
Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522-30. https://doi.org/10.1111/epi.13670
Meinardi H, Scott RA, Reis R, Sander JW, ILAE Commission on the Developing World. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia. 2001;42(1):136-49.
Kwon CS, Wagner RG, Carpio A, Jetté N, Newton CR, Thurman DJ. The worldwide epilepsy treatment gap: a systematic review and recommendations for revised definitions-a report from the ILAE Epidemiology Commission. Epilepsia. 2022. https://doi.org/10.1111/epi.17112.
Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer Dement. 2017;13(1):1-7.
Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F, EPICOS Group. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia. 2004;45:171-8.
Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia. 2000;41(3):342-51.
Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy-data from a multicentre observational study (Episcreen). Pharmacoeconomics. 2000;17(2):197-208. https://doi.org/10.2165/00019053-200017020-00008
Bolin K, Lundgren A, Berggren F, Kallen K. Epilepsy in Sweden: health care costs and loss of productivity-a register-based approach. Eur J Health Econ. 2012;13(6):819-26. https://doi.org/10.1007/s10198-011-0361-8
De Zelicourt M, Buteau L, Fagnani F, Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Seizure. 2000;9:88-95.
Garcia-Contreras F, Constantino-Casas P, Castro-Rios A, Nevarez-Sida A, Estrada Correa Gdel C, Carlos Rivera F, et al. Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res. 2006;37(3):376-83. https://doi.org/10.1016/j.arcmed.2005.07.005
Guerrini R, Battini R, Ferrari AR, Veggiotti P, Besana D, Gobbi G, et al. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia. 2001;42:641-6.
Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology. 2000;19(2):87-99.
Hong Z, Qu B, Wu XT, Yang TH, Zhang Q, Zhou D. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia. 2009;50(10):2192-8.
Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia. 2011;52(5):949-56. https://doi.org/10.1111/j.1528-1167.2010.02946.x
Kotsopoulos IA, Evers SM, Ament AJ, Kessels FGH, de Krom MCTFM, Twellaar M, et al. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res. 2003;54(2-3):131-40.
Libby AM, Ghushchyan V, McQueen RB, Slejko JF, Bainbridge JL, Campbell JD. Economic differences in direct and indirect costs between people with epilepsy and without epilepsy. Med Care. 2012;50:928-33.
Noda AH, Hermsen A, Berkenfeld R, Dennig D, Endrass G, Kaltofen J, et al. Evaluation of costs of epilepsy using an electronic practice management software in Germany. Seizure. 2015;26:49-55.
Nsengiyumva G, Druet-Cabanac M, Nzisabira L, Preux PM, Vergnenegre A. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia. 2004;45(6):673-7.
Sancho J, Pena P, Rufo M, Palacios G, Masramon X, Rejas J, et al. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of- illness study (LINCE study). Epilepsy Res. 2008;81(2-3):176-87. https://doi.org/10.1016/j.eplepsyres.2008.05.008
Strzelczyk A, Schubert-Bast S, Reese JP, Rosenow F, Stephani U, Boor R. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86-91.
Strzelczyk A, Nickolay T, Bauer S, Haag A, Knake S, Oertel WH, et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav. 2012;23:451-7.
Tetto A, Manzoni P, Millul A, Beghi E, Garattini L, Tartara A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res. 2002;48(3):207-16.
Thomas SV, Sarma PS, Alexander M, Pandit L, Shekhar L, Trivedi C, et al. Economic burden of epilepsy in India. Epilepsia. 2001;42(8):1052-60. https://doi.org/10.1046/j.1528-1157.2001.0420081052.x
Wilner AN, Sharma BK, Soucy A, Krueger A. Health plan paid cost of epilepsy in 2009 in the US. Epilepsy Behav. 2012;25:412-6.
Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy in the United States. Epilepsia. 2009;50(10):2186-91. https://doi.org/10.1111/j.1528-1167.2009.02159.x